Active Ingredient History
Latanoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is also known by the brand name of Xalatan manufactured by Pfizer. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Alopecia Areata (Phase 4)
Blood Pressure (Phase 4)
Corneal Diseases (Phase 3)
Diabetic Retinopathy (Phase 4)
Dry Eye Syndromes (Phase 4)
Eye Diseases (Phase 4)
Glaucoma ()
Glaucoma, Angle-Closure (Phase 4)
Graves Ophthalmopathy (Phase 4)
Healthy Volunteers (Phase 4)
Intraocular Pressure (Phase 2)
Macular Edema (Phase 4)
Meniere Disease (Phase 2)
Pigmentation (Phase 4)
Tears (Phase 4)
Uveitis, Anterior (Phase 4)
Vitiligo (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue